A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Sponsor: Allergan Sales, LLC
Listed as NCT03573908, this PHASE3 trial focuses on Irritable Bowel Syndrome Characterized by Constipation and remains completed. Sponsored by Allergan Sales, LLC, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period.
This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2020 — Dec 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan Sales, LLC
- Ironwood Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .